Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
VERTRATECH KIMYA SANAYI VE TICARET LIMITED SIRKETI has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner and a distinct art unit. The current prosecution profile is very narrow, focusing on a single interaction within the patent office. This concentration allows the company to dedicate its resources to a single point of interaction with the patent office for its active matters.
Stevens, Mark V is the busiest examiner for the portfolio, overseeing the pending office action. As this is the only pending action for the company, this examiner's review is the primary focus of the active prosecution. The alignment of the action with the examiner and the art unit suggests a highly specific technical application is being pursued. Practitioners should analyze the examiner's past behavior in this art unit to anticipate potential hurdles and streamline the response process.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STEVENS, MARK V | 1 | 65.5% | +41.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18687936 | SOME GEL FORMULATIONS THAT PROVIDE WOUND HEALING AND THE SYNTHESIS OF DYSPROSIUM ERBIUM BORATE TRIHYDRATE (Dy0.5Er0.5BO3.3H2O) COMPOUND USED IN THESE FORMULATIONS | STEVENS, MARK V | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18687936 | SOME GEL FORMULATIONS THAT PROVIDE WOUND HEALING AND THE SYNTHESIS OF DYSPROSIUM ERBIUM BORATE TRIHYDRATE (Dy0.5Er0.5BO3.3H2O) COMPOUND USED IN THESE FORMULATIONS | STEVENS, MARK V | — |
| Art Unit | Apps |
|---|---|
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18687936 | SOME GEL FORMULATIONS THAT PROVIDE WOUND HEALING AND THE SYNTHESIS OF DYSPROSIUM ERBIUM BORATE TRIHYDRATE (Dy0.5Er0.5BO3.3H2O) COMPOUND USED IN THESE FORMULATIONS | STEVENS, MARK V | 1613 | §103§112 | Non-Final OA | — | Pending | Feb 29, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial